COMBIPRES
LOE ApproachingNDAORALTABLETPriority Review
Approved
Sep 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIPRES is an oral tablet combination product approved in 1974 by Boehringer Ingelheim as a small-molecule NDA. The specific indication and mechanism of action are not disclosed in available data, limiting clinical characterization.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling a contracted commercial footprint and reduced hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COMBIPRES currently shows zero linked job openings, reflecting its LOE-approaching lifecycle and declining commercial priority. Roles available are predominantly defensive commercial positions focused on market maintenance rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on COMBIPRES at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.